EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation of the Finnish Diabetes Risk Score (FINDRISC) in a Central‐European Population for the Prediction of Cumulative Incidence of Type 2 Diabetes Over 8‐Years—Follow‐Up of the Budakalász Health Examination Survey (BHES)

Zsolt Bagyura iD, Loretta Zsuzsa Kiss, István Panykó iD, Beatrix Annamária Domján, Pál Soós, Zsolt Szelid, Béla Merkely, Ádám Gyula Tabák

Diabetes/Metabolism Research and Reviews · 2025

DOI: 10.1002/dmrr.70105 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Zsolt Bagyura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heart and Vascular Center, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development, and Innovation Fund NRDIF of Hungary, European Commission, UK Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

FINDRISC is widely used to assess 10‐year incidence of drug‐treated type 2 diabetes; however, it may require recalibration before implementation in new populations. Thus, we investigated the performance of FINDRISC and recalibrated it in the Hungarian population.

Methods

8‐year follow‐up data for incident type 2 diabetes was ascertained from the reimbursement database of Hungary for 2059 diabetes‐free participants of a voluntary survey (2011–2013). Incident diabetes was based on repeated prescription of antidiabetic medications. Discrimination of the original and the recalibrated (multiple logistic regression) FINDRISC was compared using ROC analysis.

Results

279 (13.6%) incident diabetes cases were found. Age, waist circumference, antihypertensive treatment, and history of elevated blood glucose were independent predictors of incident diabetes. Re‐estimating the weights improved discrimination ([AUC]: 0.68 [95% CI 0.65–0.71] vs. original: 0.66 [95% CI 0.63–0.69], p = 0.02). Even after the omission of variables non‐independent predictors of diabetes, the AUC remained better than the original score and similar to the reweighted score (AUC: 0.68 [95% CI 0.65–0.71] vs. original p = 0.04 vs. reweighted model p = 0.83). Discrimination was worse for those ≥ 65 years versus younger people.

Conclusions

Validation and recalibration are important steps before using the FINDRISC in a population different from the derivation cohort. Omission of some variables (physical activity, fruit and vegetable consumption, and family history of diabetes) that are not readily available did not significantly worsen the performance of the model. FINDRISC may not be a good predictor of incident diabetes in older populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansFemaleMaleMiddle AgedFollow-Up StudiesIncidenceRisk FactorsAdultHealth SurveysAgedPrognosisRisk AssessmentHungaryFinland

Stichwörter der Autor:innen

FINDRISC—Finnish diabetes risk scoreT2DM—type 2 diabetes mellitusrecalibrationvalidation

Autor:innen und Institutionen

  • Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, Budapest, Hungary.
  • Károly Rácz Conservative Medicine Division, Doctoral College, Semmelweis University, Budapest, Hungary.
  • Department of Gynaecology and Obstetrics, Komárom-Esztergom County Szent Borbála Hospital, Tatabánya, Hungary.
  • Institute of Preventive Medicine and Public Health, Semmelweis University Faculty of Medicine, Budapest, Hungary.
  • UCL Brain Sciences, University College London, London, UK.

ORCID-Profile: Zsolt Bagyura, István Panykó

Förderung

  • National Research, Development, and Innovation Fund NRDIF of Hungary
  • European Commission
  • UK Medical Research Council
  • Ministry of Innovation and Technology, Hungary
  • Ministry of Culture and Innovation, Hungary
  • HORIZON-HLTH-2023-TOOL-05
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Bagyura, Z., Kiss, L. Z., Panykó, I., Domján, B. A., Soós, P., Szelid, Z., Merkely, B., & Tabák, Á. G. (2025). Validation of the Finnish Diabetes Risk Score (FINDRISC) in a Central‐European Population for the Prediction of Cumulative Incidence of Type 2 Diabetes Over 8‐Years—Follow‐Up of the Budakalász Health Examination Survey (BHES). Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70105

Vancouver

Bagyura Z, Kiss LZ, Panykó I, Domján BA, Soós P, Szelid Z, et al. Validation of the Finnish Diabetes Risk Score (FINDRISC) in a Central‐European Population for the Prediction of Cumulative Incidence of Type 2 Diabetes Over 8‐Years—Follow‐Up of the Budakalász Health Examination Survey (BHES). Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70105

BibTeX
@article{Bagyura2025,
  author = {Bagyura, Zsolt and Kiss, Loretta Zsuzsa and Panykó, István and Domján, Beatrix Annamária and Soós, Pál and Szelid, Zsolt and Merkely, Béla and Tabák, Ádám Gyula},
  title = {Validation of the Finnish Diabetes Risk Score (FINDRISC) in a Central‐European Population for the Prediction of Cumulative Incidence of Type 2 Diabetes Over 8‐Years—Follow‐Up of the Budakalász Health Examination Survey (BHES)},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  doi = {10.1002/dmrr.70105}
}
Kostenlos starten →